Nkarta reports Q3 net loss of $22.4M; NKX101 data pushed to 1H 2022

Nkarta, Inc.

2022-Q3 EPS reported -$1.93

Net loss of $22.4M ($0.68 per share); R&D expense $16.6M, G&A $5.8M.
Cash, equivalents, restricted cash and short-term investments totaled $259.8M; runway into at least 2H 2023.
NKX101 Phase 1 data for AML/MDS expected in 1H 2022 (updated from prior guidance).
First patients dosed in NKX019 Phase 1 for B cell malignancies; initial data expected in 2022.
Leased new 88,000 sq ft manufacturing facility and HQ to support pivotal trials and commercial launch.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.